The first clinical trial of an ADC against myeloma, which is now of more historical interest, utilized the CD19-targeted anti-B4 antibody linked to blocked ricin and was based on the rationale that CD19 may be present on myeloma clonogenic cells [26,27]. This evidence concerns the gene CD19 and plasma cell myeloma.